卡托普利对高血压与血管结构及功能的分离效应(英文)  

Disparate effects of captopril on hypertension and blood vessel

作　　者：陈达光[1] 晋学庆[1] 王华军[1] 陈松苍[1] 

机构地区：[1]福建医学院附属第一医院高血压研究室

出　　处：《中国药理学报》1996年第2期133-138,共6页Acta Pharmacologica Sinica

基　　金：supported by the National Natural Science Fundation of China,№ 3880409;Presented at 15th Scientific Meeting of International Society of Hypertension (Melbournet,1994 Mar 20-24).

摘　　要：目的:研究卡托普利(Cap)对血管的结构与功能的作用是否与其降压作用分离。方法:SHR从胎仔期起分别接受Cap 20与100mg·kg^(-1)·d^(-1),A组和B组)至生后16周停药,40周实验。血压用尾动脉法测定。肠系膜动脉第三级分支的壁/腔比测定用形态计量法,阻力血管性质测定用后肢灌注压对递增量phenylephrine,灌注液内加L-NAME或L-arginine。结果:两种剂量的Cap都能完全 防止血管壁肥厚(肠系膜动脉第三级分支的壁/腔比Cap A:0.38±0.08,Cap B:0.29±0.05 vsWKY:0.34±0.11,P>0.05)结果与WKY者类似。Cap组后肢灌注压曲线的参数与WKY组几乎完全相同,与未治疗SHR有明显差别(EC_(50),Cap B:4.05±2.58 vs SHR:1.15±0.96 mL·L^(-1),P<0.01,vs WKY:5.13±1.97mL·L^(-1),P>0.05)。在灌注液内加入L-NAME或L-arginine可加强或减弱Cap治疗组的血管收缩反应。结论:Cap从胎仔期治疗可以使SHR的阻力血管结构与收缩反应正常化,而血压仍维持在不同程度的较高水平。AIM: To study whether the effect of captopril (Cap) on vascular structure and function may be separated from its effect on blood pressure. METHODS: Captopril treatment ( group Cap A and B, 20 and 100 mg·kg-1·d-1) was given to SHR rats during pregnancy, weaning, and up to 16 wk of age. Study performed at 40 wk. Blood pressure ( BP) was measured by tail-cuff sphygmo-manometer, and wall/lumen ratio of mesenteric artery 3rd grade branch was assessed by morphome-tric assay. Resistance vessel properties were determined by hindquarter perfusion pressure responses to incremental doses of phenylephrine, in the presence of Nw nitro-L-arginine methyl ester ( L-NAME) or the L-arginine, the precursor of nitric oxide synthesis. RESULTS: Both doses of Cap prevented hypertrophy of blood vessels to an extent comparable to that of the untreated WKY rats (wall/lumen ratio of mesenteric artery, Cap A: 0.38 ± 0.08, CapB: 0.29 ±0.05 vs WKY: 0.34 ±0.11, P>0.05, respectively) . The parameters derived from hindquarter perfusion pressure curves in Cap treated group were almost identical to that of WKY, significantly different from that of untreated SHR (EC50, Cap B 4.05 μ2.58 vs SHR 1.15 ±0.96mL·L-1, P<0.01; vs WKY 5.13 ± 1.97 mL · L-1, P > 0.05). Addition of L-NAME or L-arginine in the perfusate augmented or attenuated the vasoconstriction responses in the Cap treated group. CONCLUSION; Cap initiated from in-trauterine period normalized the vascular structure and vasoconstrictive responses in SHR when BP still sustained at a higher level vs WKY.

关 键 词：高血压 卡托普利 血管收缩 大鼠 

分 类 号：R544.1[医药卫生—心血管疾病] R972.4[医药卫生—内科学]